In contrast, patients treated with BM-MSCs showed VAS improvement at 6-, 12-, and 24-month follow-ups, but WOMAC showed no statistical significance, even though there was a positive trend during follow-up.
← all excerpts
Mesenchymal Stem Cell Mechanisms of Action and Clinical Effects in Osteoarthritis: A Narrative Review.
1
—
—